1-[2-(3-Azabicyclo[3.1.0]hexan-3-yl)-4-[[4-(azidomethoxy)-3-chlorophenyl]methoxy]-1,2,3,4-tetrahydropyrimidin-5-yl]ethanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-[2-(3-Azabicyclo[3.1.0]hexan-3-yl)-4-[[4-(azidomethoxy)-3-chlorophenyl]methoxy]-1,2,3,4-tetrahydropyrimidin-5-yl]ethanone
• 英文别名: 1-[2-(3-azabicyclo[3.1.0]hexan-3-yl)-4-[[4-(azidomethoxy)-3-chlorophenyl]methoxy]-1,2,3,4-tetrahydropyrimidin-5-yl]ethanone
• 化学式: C19H23ClN6O3
• 分子量: 418.9
• InChiKey: YODKFTATFNUYFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：EP2735567A1

  公开（公告）日：2014-05-28

  The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by General Formula (I) and its pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description, the present invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition in preparation of a medicine for enhancing a cGMP signal transduction function or a medicine for treating or preventing sexual dysfunction and diseases with lower urinary tract symptoms.

  本发明涉及医药技术领域，尤其涉及一种由通式(I)代表的杂环取代的嘧啶化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5如描述中所定义，本发明还涉及该化合物的制备方法、本发明还涉及该化合物的制备方法、含有该化合物的药物组合物，以及该化合物和药物组合物在制备增强 cGMP 信号转导功能的药物或治疗或预防性功能障碍和下尿路症状疾病的药物中的用途。